Back to Browse Journals » International Journal of Women's Health » Volume 1

Mandatory fortification with folic acid in the United States appears to have adverse effects on histone methylation in women with pre-cancer but not in women free of pre-cancer

Authors Chandrika J Piyathilake, Maurizio Macaluso, Jorge E Celedonio, et al

Published 21 September 2009 Volume 2009:1 Pages 131—137

DOI http://dx.doi.org/10.2147/IJWH.S6521

Review by Single-blind

Peer reviewer comments 3

Chandrika J Piyathilake1, Maurizio Macaluso2, Jorge E Celedonio1, Suguna Badiga1, Walter C Bell3, William E Grizzle3

1Department of Nutrition Sciences, 2School of Public Health, 3Department of Pathology of The University of Alabama at Birmingham, AL, USA

Objective: To evaluate whether mandatory fortification of grain products with folic acid in the US is associated with changes in histone methylation in cells involved in cervical carcinogenesis.

Methods: Cervical specimens obtained before (1990 to 1992) and after mandatory folic acid fortification (2000 to 2002) were used to examine the degree of histone methylation (H3 Lys-9) by immunohistochemistry. 91 women (51 before and 40 after fortification) were diagnosed with cervical intraepithelial neoplasia (CIN) grade 3 or carcinoma in situ (CIS) and sections utilized in the study also contained normal, reactive or metaplastic cervical epithelium, CIN 1 or CIN 2. 64 women (34 before and 30 after fortification) were free of CIN and these sections contained only normal or reactive cervical epithelium. Immunohistochemical staining for H3 Lys-9, its assessment in different cell or lesion types and data entry were blinded for fortification status. For each cell type or lesion category we used PROC MIXED in SAS with the specimen identifier as a random effect and the robust variance estimator to estimate age- and race-adjusted intensity score for H3 Lys-9 in the pre- and post-fortification periods.

Results: Degree of H3 Lys-9 methylation was significantly higher (P < 0.0001) in ≥CIN 2 lesions (CIN 2, CIN 3 and CIS) than in ≤CIN 1 lesions (CIN 1, normal, reactive and metaplastic), in both pre- and post-fortification CIN 3/CIS specimens. Age- and race-adjusted mean H3 Lys-9 score was significantly higher in all cell or lesion types in CIN 3/CIS specimens obtained in the post-fortification period compared to pre-fortification period (P < 0.05, all comparisons). In contrast, in specimens obtained from women free of CIN, Lys-9 methylation in normal/reactive cervical epithelium was significantly lower in post-fortification specimens than in pre-fortification specimens (P = 0.03).

Conclusions: Higher levels of Lys-9 methylation in ≥CIN 2 compared to ≤CIN 1 lesions suggest that higher Lys-9 methylation is associated with progression of lower grade CIN to higher grade CIN. Higher Lys-9 methylation in cervical tissues of women diagnosed with CIN 3 in the postfortification period than in pre-fortification period suggest that fortification may adversely affect histone methylation in already initiated cells. Lower Lys-9 methylation in normal/reactive cervical cells of women free of CIN in the post-fortification period than pre-fortification on the other hand suggests that fortification is likely to protect against initiation of carcinogenic process in the cervix. These results suggest that mandatory fortification with folic acid in the US seems to have different effects on cancer depending on the stage of carcinogenesis. Because this is the first study to report folic acid fortification-associated differences in histone methylation and because of the limitations inherent to the approach we have taken to demonstrate these differences, validation of the results in other study populations or with other techniques for assessing histone methylation is necessary.

Keywords: folic acid, fortification, histone methylation, cervix

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

A comparison of folate status in women of child-bearing age in Korea and in the United States

Hyun T, Badiga S, Jang HB, Han YH, Piyathilake CJ

Nutrition and Dietary Supplements 2012, 4:47-53

Published Date: 12 July 2012

Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race

Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ

International Journal of Women's Health 2011, 3:185-192

Published Date: 12 July 2011

Readers of this article also read:

Current and emerging management options for patients with Morquio A syndrome

Algahim MF, Almassi GH

Therapeutics and Clinical Risk Management 2013, 9:45-53

Published Date: 11 February 2013

The feasibility of a fiber optic laser approach to relieving lymphedematous syndrome: a case report

Palmieri B, Di Cerbo A, Rottigni V, Fistetto G, Iannitti T

OncoTargets and Therapy 2013, 6:85-88

Published Date: 11 February 2013

Controlled-release approaches towards the chemotherapy of tuberculosis

Saifullah B, Hussein MZ, Hussein Al Ali SH

International Journal of Nanomedicine 2012, 7:5451-5463

Published Date: 12 October 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia

Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A

OncoTargets and Therapy 2011, 4:149-168

Published Date: 5 September 2011

Topical diclofenac in the treatment of osteoarthritis of the knee

Niklas Schuelert, Fiona A Russell, Jason J McDougall

Orthopedic Research and Reviews 2011, 3:1-8

Published Date: 6 February 2011

Current and developing therapeutic agents in the treatment of Chagas disease

Werner Apt

Drug Design, Development and Therapy 2010, 4:243-253

Published Date: 17 September 2010

Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis

Safaa Sebak, Maryam Mirzaei, Meenakshi Malhotra, et al

International Journal of Nanomedicine 2010, 5:525-532

Published Date: 15 September 2010

Differential effects of nanoselenium doping on healthy and cancerous osteoblasts in coculture on titanium

Phong A Tran, Love Sarin, Robert H Hurt, et al

International Journal of Nanomedicine 2010, 5:351-358

Published Date: 10 May 2010